Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.H. Nüßlein, Manuela Le Bars, P. Peichl et al.|PubMed|2016Cited by 32
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trialKoray Taşçılar, Jürgen Rech, Melanie Hagen et al.|The Lancet Rheumatology|2021Cited by 31
IgA anti-citrullinated protein antibodies are associated with flares during DMARD tapering in rheumatoid arthritisMaria Sokolova, Jörg Henes, Melanie Hagen et al.|Lara D. Veeken|2021Cited by 17
Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody StatusMelanie Hagen, Jürgen Rech, Matthias Englbrecht et al.|The Journal of Rheumatology|2018Cited by 11